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Highlights 
 ADHD is a neurodevelopmental disorder that affects an increasing number of people 
worldwide. 
 Zebrafish is a prominent model to assess the underlying mechanisms of ADHD and it 
comorbidities. 
 Advantages and disadvantages of using zebrafish to model ADHD were discussed. 
 Current zebrafish ADHD models and future directions are highlighted. 
 
Abstract 
Attention deficit hyperactivity disorder (ADHD) is a common, debilitating 
neurodevelopmental disorder associated with inattentiveness, pathological hyperactivity and 
impulsivity. Despite the mounting human and animal evidence, the neurological pathways 
underlying ADHD remain poorly understood. Novel translational model organisms, such as the 
zebrafish (Danio rerio), are becoming important tools to investigate genetic and pathophysiological 
mechanisms of various neuropsychiatric disorders. Here, we discuss ADHD etiology, existing 
rodent models and their limitations, and emphasize the advantages of using zebrafish to model 
ADHD. Overall, the growing utility of zebrafish models may improve our understanding of ADHD 
and facilitate drug discovery to prevent or treat this disorder. 
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1. Introduction  
Attention deficit hyperactivity disorder (ADHD) is a common debilitating 
neurodevelopmental disorder that affects approximately 8% - 12% of children worldwide, with 
most symptoms persisting into adulthood (Faraone et al., 2003; Polanczyk et al., 2015). Clinically, 
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ADHD is characterized by increased levels of  hyperactivity, impulsivity and inattention (Halperin 
et al., 1992; Spencer et al., 2007; Wolraich et al., 1996), often seen with distractibility, fidgeting 
and excessive talking (Wilens et al., 2010). Although currently recognized major subtypes of this 
disorder include hyperactive, inattentive and mixed-type (Riccio et al., 2006; Sagvolden et al., 
2005a), ADHD is likely to be caused, and mediated, by a number of different genes and 
neurophenotypes (Faraone, 2018; Gillis et al., 1992; Goodman, 1989; Schmitz et al., 1995; 
Stevenson, 1992). There are several behaviors associated with ADHD that are transdiagnostic 
for comorbid and related disorders, suggesting common mechanisms (Carey et al., 2016; Farb 
and Ratner, 2014; Sharp et al., 2014; Sternat and Katzman, 2016). For example, adult ADHD 
is often comorbid with affective and substance abuse disorders, and has been linked to 
increased risk of traffic accidents, criminal offenses and other psychosocial problems 
(Anastopoulos et al., 2018; Kessler et al., 2006; Marraccini et al., 2017). The developmental 
cognitive dysfunctions in ADHD severely impair individual’s ability to function in academic, 
occupational and social settings (DuPaul et al., 2006; Wehmeier et al., 2010). Overall, ADHD is 
unlikely to be linked to one specific mechanism but to many different combinations of aberrant 
changes in dopaminergic, noradrenergic and serotonergic systems (Cortese, 2012; Potter et al., 
2014; Purper-Ouakil et al., 2011). Thus, the etiology of ADHD almost certainly involves the 
interaction of genetic and environmental factors (e.g., premature birth, maternal smoking or alcohol 
consumption during pregnancy) (Bidwell et al., 2018).  
The pharmacological treatments of ADHD includes psychostimulants (e.g., 
methylphenidate and d-amphetamine derivatives) and non-psychostimulant medication (e.g., 
atomoxetine, clonidine and guanfacine) (Cortese and Angriman, 2017; Jensen et al., 1999; 
Michelson et al., 2001; Safer et al., 1996; Stein et al., 1996). Other treatments for ADHD include 
cognitive behavioral therapy (CBT), especially efficient when combined with pharmacotherapy 
(Adesman, 1992; Goode et al., 2018; Mongia and Hechtman, 2012; Safren et al., 2005). Although 
pharmacotherapies do alleviate ADHD symptoms, they have limited efficacy, numerous adverse 
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effects, and often fail to treat or prevent the manifestation of the full-blown disorder (Chu et 
al., 2017). To improve our understanding of ADHD pathobiology, several rodent models of this 
disorder have been developed (Kostrzewa et al., 2008; Sagvolden et al., 2005a; van der Kooij and 
Glennon, 2007). However, none of them fulfil all validity criteria, such as the expression of 
combinate ADHD-related behaviors and shared neurological pathways (Sontag et al., 2010). 
Therefore, it is critical to develop, innovate and validate alternative complementary models to 
further explore ADHD-related mechanisms. 
The zebrafish (Danio rerio) is an increasingly popular animal model in neuroscience and 
biological psychiatry (Meshalkina et al., 2017; Orger and de Polavieja, 2017). Their robust 
behavioral repertoire (Kalueff et al., 2013), the availability of well-established behavioral tests  
(Parker et al., 2013; Parker et al., 2012), and the power of automated behavioral testing soft- and 
hardware (Carreno Gutierrez et al., 2018; Parker et al., 2013), make zebrafish a useful animal model 
of human brain disorders. Here, we discuss the advantages and limitations of zebrafish ADHD 
models, and their utility for probing molecular and genetic mechanisms of this disorder. We also 
outline the importance of further validation of ADHD models using zebrafish, and critically evaluate 
their value for searching novel treatments for this disorder. 
 
2. Neurological and genetic bases of ADHD 
 Although ADHD is strongly linked to environmental factors, various genetic, biochemical 
and neural bases of this disorder have been identified (Bonvicini et al., 2016; Comings et al., 2000; 
Hawi et al., 2015; Paclt et al., 2005). Table 1 summarizes genes consistently implicated in clinical 
ADHD. Multiple human genes that co-segregate with ADHD include those regulating central 
dopaminergic, serotonergic and noradrenergic systems (Lesch et al., 2008; Zhang et al., 2012) (Fig. 
1). These genetic and neurobiological associations are further supported by the clinical efficacy of 
stimulant medications that interacts with monoaminergic signaling in animal models (Gainetdinov 
et al., 1999; Giros et al., 1996; Russell, 2011). Importantly, although ADHD-linked genes 
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independently confer a small risk for ADHD, they offer the framework for genetic mapping of likely 
candidates to probe their role in this disorder (Field et al., 2013; Gold et al., 2014). Both common 
and rare genetic variants confer ADHD risk (Lo et al., 2003; Martin et al., 2015), and may be 
important for developing novel individualized treatments (Gold et al., 2014). Concerning ADHD 
hereditability, twin studies have demonstrated that genetic additive and dominant effects are strong 
components (around 75%) of child and adolescent ADHD (Faraone et al., 2005).  Furthermore, 
inhibitory control deficits act as a cognitive marker of genetic risk, and are shared with non-affected 
first degree relatives (Goos et al., 2009); however, ADHD patterns of inheritance are certainly not 
Mendelian, and are far from being fully elucidated (Freitag et al., 2010). 
In humans, there are several approaches to study ADHD which combine performance-
related measures with intermediate measures of behavior and neurobiology, such as neural imaging 
and psychophysiological analysis (Luman et al., 2010).  For example, magnetic resonance imaging 
(MRI) has demonstrated that dopaminergic release is correlated with BOLD responses in the ventral 
striatum (Knutson and Gibbs, 2007). Such neural imaging studies are very encouraging and provide 
the basis for future research; however, the number of these studies is relatively scarce (Plichta et al., 
2009; Rubia et al., 2009; Scheres et al., 2006; van Meel et al., 2005). Pharmacological interventions 
are widely used to research ADHD in humans, including in particular the clinical efficacy of 
catecholaminergic agonists and re-uptake inhibitors (McCarthy, 2014; Weyandt et al., 2014). 
Although human research offers the opportunity to observe the disorder in situ, there are several 
limitations when working with humans in terms of elucidating mechanisms, including ethical 
constraints, but also population variations and individual variation in, and lack of specificity of, 
responses to treatment (Hall and Myers, 2016). Here, we discuss the role of different animal models 
of ADHD, their clinical and translational relevance, the existing limitations and future studies in 
this field.  
 
3. Traditional animal models of ADHD  
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 Developing animal models should have sufficient face and construct validity (Willner, 
1986). For ADHD, a model should mimic fundamental behavioral characteristics -- impulsiveness, 
sustained inattention and hyperactivity -- that develop over time (Russell et al., 2005; Sagvolden et 
al., 2005b). Currently, rodent models are most commonly used to study ADHD (Davids et al., 2003; 
Fan et al., 2012; Tripp and Wickens, 2012), as both rats and mice exhibit overt hyperactivity, 
impulsivity and attention deficits, thereby providing adequate face validity as ADHD models 
(Russell, 2007, 2011; Russell et al., 2005). For example, the dopamine transporter (DAT) knockout 
mice display ADHD-like hyperactivity and learning deficits (Gainetdinov et al., 1999), but unlike 
adults and children with ADHD show  lower expression of DAT (Cheon et al., 2003; Dougherty et 
al., 1999; Krause et al., 2000). Other models of ADHD-related neurotransmitter deficits include 
mutants with aberrant serotonin (Bouwknecht et al., 2001; Brunner et al., 1999; Smoller et al., 2006; 
Zhuang et al., 1999) and glutamate systems (Callaway et al., 1992; Rempel et al., 1993). Although 
showing reasonable face, construct and predictive validity, some expected ADHD-like phenotypes 
(e.g., hyperactivity or inattention) are not expressed simultaneously by these mutants. 
 While rodent or non-human primate models are critical for dissecting behavioral and neural 
mechanisms of ADHD, they are expensive and generally time-consuming (Sontag et al., 2010). 
Therefore, alternative models with the potential for high-throughput screening to identify genetic 
alterations and new pharmacological treatments have an important role in uncovering the 
mechanisms of ADHD and it comorbidities (Amsterdam and Hopkins, 2006; Kalueff et al., 2014b; 
Mezzomo et al., 2018; Parng et al., 2002). As will be discussed further, the zebrafish is an 
important complementary model that has high face, construct and predictive validity, and has 
the potential to assist in the challenge of understanding ADHD. 
4. Zebrafish as an alternative model for ADHD  
The zebrafish continues to emerge as a novel model organism to study shared, evolutionarily 
conserved ‘core’ mechanisms of complex psychiatric disorders (Howe et al., 2013; Kalueff et al., 
2014b; Postlethwait et al., 2000; Stewart et al., 2015). Zebrafish are easy to breed (Nasiadka and 
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Clark, 2012), their embryos develop externally and the transparency of the eggs facilitates 
developmental studies, and manipulation of neural circuits in vivo, Fig. 2.  (Fetcho and Liu, 1998; 
Kyun Ko et al., 2011; Meng et al., 2008; Norton, 2013). 
The utility of both larval and adult zebrafish in neuroscience has considerably grown 
recently due to their high genetic and physiological similarity to other vertebrates, including 
humans, relative ease of genetic manipulation, and homologous CNS functions and anatomy 
(Gerlai, 2010a, b, 2011). Despite topographical differences between fish and mammalian brain 
structures, the neuronal pathways involved in zebrafish brain physiology are generally highly 
conserved, including all major neurotransmitter systems (Higashijima et al., 2004; McLean and 
Fetcho, 2004; Panula et al., 2010; Thakkar, 2011; Tropepe and Sive, 2003). The zebrafish genome 
has been fully sequenced, where approximately 70% of human genes have at least one obvious 
zebrafish orthologue (Howe et al., 2013). Furthermore, a large number of genes have been 
targeted to develop zebrafish mutant lines using genome editing technology for forward and 
reverse genetic studies (i.e., using CRISPR (Clustered regularly interspaced short palindromic 
repeats) (Hruscha et al., 2013), TALENs (Transcription activator-like effector nucleases) (Clark et 
al., 2011), gene-breaking transposon-based approaches (Heintze et al., 2013), TILLING (Targeting 
Induced Local Lesions in Genomes method) (Moens et al., 2008), viral vector-mediated insertional 
mutagenesis (Amsterdam and Hopkins, 2006), morpholino antisense oligonucleotides (Bill et al., 
2008), optogenetics (Nagel et al., 2003; Zhang et al., 2007)), and these screens have recently been 
combined with in vivo visualizing of neural activity and electrophysiological recording 
(Higashijima et al., 2003; Stewart et al., 2015). 
Behavioral phenotypes of zebrafish provide important insights into neural mechanisms of 
normal and pathological brain function (Champagne et al., 2010; Kalueff et al., 2013; Spence et al., 
2008). The well-characterized behavioral repertoire of zebrafish spans the domains of locomotor 
activity, aggression, anxiety, sociability and cognition, often associated with neuropsychological 
disorders (Buske and Gerlai, 2011; Jones and Norton, 2015; Levin et al., 2007; Maximino et al., 
2015; Stewart et al., 2011; Stewart et al., 2014). Although the functions of genes involved in 
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psychiatric disorders are still relatively understudied in zebrafish, this species may also provide 
novel genetic information related to neuropsychiatric disorders (Norton, 2013). 
The advantages and limitations of zebrafish as a model in translational neuroscience research 
have been extensively discussed elsewhere (Fontana et al., 2018; Kalueff et al., 2014a; Kalueff et 
al., 2014b; Lieschke and Currie, 2007; Nguyen et al., 2013; Stewart et al., 2014; Stewart et al., 
2015), and will not be addressed here in depth. However, in addition to many important advantages, 
the use of zebrafish models in neuropsychiatric disorders presents some limitations (Stewart et al., 
2014), including species differences in brain development (Ito and Yamamoto, 2009) and anatomy 
vs. mammals (Aizawa, 2013), as well as genome duplication in teleost fishes (Lu et al., 2012). 
Because of this, many zebrafish genes have two copies, where mammals have only one copy (Lu et 
al., 2012). The resulting genetic difference can complicate the analysis of specific genes associated 
with diseases, particularly if the effect of a mutated gene is masked by unaltered paralogous gene 
(Stewart et al., 2015). Finally, while psychiatric illnesses  remain among the most poorly treated 
diseases (Kokel and Peterson, 2008), the large-scale drug screens in mammals are inefficient and 
impractical (Kokel and Peterson, 2008). Thus, the zebrafish becomes an important model for 
medium-and high-throughput behavior-based drug discovery (Rihel et al., 2010; Rihel and Schier, 
2012). Combining in vivo relevance of behavior-based phenotyping with the automation of modern 
drug-screening technologies, zebrafish provide a powerful approach to improve our understanding 
of ADHD neurobiology and accelerate psychiatric drug discovery (Kokel and Peterson, 2008). 
Finally, zebrafish screens help examine various brain genes implicated in ADHD (Huang et al., 
2015; Lange et al., 2018; Lange et al., 2012; Martinez et al., 2016), collectively becoming a 
promising organism in this field (Stewart et al., 2015).  
 
4.1. Behavioral tests to study ADHD in zebrafish 
All three ADHD-related phenotypes - inattention, impulsiveness and hyperactivity 
(Winstanley et al., 2006) have already been described in zebrafish using automated video-analyses 
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(Cahill, 2007; Creton, 2009; Gerlai et al., 2000; Kalueff et al., 2013; Parker et al., 2013). For 
example, the five-choice serial reaction time task (5-CSRTT) assesses impulsiveness and attention, 
two important ADHD-related behaviors, by measuring the ability of adult zebrafish to respond to 
one of five perceptually identical stimuli (presented in one of five distinct spatial locations) which 
appear randomly after a variable inter-trial interval (ITI) (Parker et al., 2014; Parker et al., 2013). 
Zebrafish perform well on the 5CSRTT, revealing noradrenergic control of zebrafish impulsivity, 
as it is reduced by acute atomoxetine (Parker et al., 2014). These data parallel those in mammals, 
and show face, construct and predictive validity of this experimental model to assess ADHD-related 
symptoms in zebrafish. However, impulse control is difficult to assess in larval animals, presenting 
a disadvantage for early-onset ADHD models in zebrafish. Despite some attempts to measure 
impulsivity of larval zebrafish, their findings have been largely correlational and open to 
interpretation (Lange et al., 2012; Parker et al., 2015). Thus, without a careful evaluation of neural 
circuits recruited in larvae during putative impulsivity, any suggestion of the potential to manipulate 
or measure impulsivity in larvae behaviorally should be taken with caution. Moreover, the role of 
attention in the zebrafish 5CSRTT is yet to be established. Interestingly, ‘correct' responses in the 
5CSRTT increased following exposure to nicotine, a cholinergic agonist known to increase attention 
in zebrafish  (Parker et al., 2014). However, as attention was not directly manipulated (i.e., by 
increasing task demand), it remains unclear if the task tested attention and whether sustained 
attention in zebrafish is under cholinergic control. 
 Common in clinical ADHD, hyperactivity can be assessed in various behavioral tests in 
zebrafish. For example, it can be assessed in larval zebrafish  (Lange et al., 2013) by placing animals 
in well-plates and recording for 5-10 min (Ingebretson and Masino, 2013; Lange et al., 2012; 
MacPhail et al., 2009; Ulhaq et al., 2013), assessing the swim episode frequency (Hz) and duration 
(ms), swim speed (mm/s), active swim time (s) and total distance swum (cm) (Ingebretson and 
Masino, 2013). The hyperactivity profile of adult zebrafish can utilize the novel tank or the open 
field tests. The novel tank test is the most commonly used test to assess locomotion and anxiety-
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like phenotypes (Blaser and Rosemberg, 2012; Stewart et al., 2011). This test consists of placing 
individual fish in a novel environment, where they usually swim in the bottom section and gradually 
increase the activity in the upper sections of a tank, assessing total distance travelled (m), average 
speed (m/s), absolute turn angle (º) and immobility (s) (Egan et al., 2009). Alterations in these 
parameters can be used for hyperactivity profiling, making this test an important tool to investigate 
ADHD-related symptoms in adult zebrafish. Similar to the novel tank, the open field assesses 
zebrafish behavior in a novel environment, typically - a plastic/glass cylinder or box virtually 
divided into center and periphery, to assess time spent (s), distance travelled (m) and number of 
visits to these pre-defined zones,  thus reflecting zebrafish locomotor and exploratory behaviors and 
thigmotaxis (preference for the  tank edges)  (Grossman et al., 2010).  Both tests may be important 
tools to assess hyperactivity in ADHD models, and together can enable a fuller characterization of 
zebrafish phenotypes. 
 
5. Current ADHD-related studies with zebrafish 
 Although zebrafish models of ADHD and other neurodevelopmental disorders are relatively 
new, their importance continues to grow (Kalueff et al., 2014a; Kalueff et al., 2014b; Norton and 
Bally-Cuif, 2010; Norton, 2013). Similar to rodents, mutant zebrafish with ablated circadian gene 
period1b (per1b) show changes in dopamine levels by disruption circadian cycle which leads to 
hyperactivity and attention deficits (Huang et al., 2015). Moreover, even the alterations of circadian 
cycle are not described as a core symptom of ADHD, this study supports the high construct validity 
of zebrafish as an ADHD model. Capitalizing on zebrafish genetic tractability, other mutant 
zebrafish show high face, construct and predictive validity as ADHD models (Fetcho and Liu, 1998; 
Fontana et al., 2018; Kalueff et al., 2014b; Norton and Bally-Cuif, 2010; Norton, 2013; Stewart et 
al., 2015). For example, knocking down the zebrafish homolog gene micall2b evokes a 
hyperactive/impulsive-like fish behaviors reversed by atomoxetine, a clinically approved anti-
ADHD (Yang et al., 2018). Related to ADHD in children, this gene codes a cytosolic multidomain 
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protein that have a role in axon guidance, myofilament organization and synaptogenesis (Beuchle 
et al., 2007; Terman et al., 2002).  
Another interesting line of research stems from the LATROPHIN3 (LPHN3) gene strongly 
linked to ADHD susceptibility clinically (Franke et al., 2012; Lange et al., 2012). Morpholino 
oligonucleotides (MOs) targeting of the lphn3.1 gene evoke several ADHD-like behaviors in 
zebrafish larvae, including hyperactivity and increased motor impulsivity (Lange et al., 2012). In 
addition, the lphn3.1 MO animals display fewer dopaminergic neurons in brain areas responsible 
for locomotion, thus strongly implicating lphn3.1 in the development of the dopaminergic system 
in zebrafish (Lange et al., 2012), similar to rodents (Wallis et al., 2012), and  ADHD. Additionally, 
the behavioral alterations of lphn3.1 MOs were reversed by both methylphenidate and atomoxetine, 
increasing the construct validity of the model (Lange et al., 2012). Zebrafish morphants lphn3.1 
have also hyposensitivity to dopamine agonists and antagonists, suggesting hyperactivation and 
saturation of dopamine signaling (Lange et al., 2018). Further studies can combine pharmacological 
agents with zebrafish lacking lphn3.1 function to help understand the functional interactions 
between LPHN3 and dopamine that lead to ADHD in humans (Lange et al., 2018). Although the 
loss of lphn3.1 function is related to ADHD-symptoms in larvae, future studies are also needed to 
better characterize the behavioral phenotypes in this model in adult zebrafish.  
ADHD is a neurodevelopmental disorder (Poelmans et al., 2011), and targeting its 
‘developmental’ aspect in zebrafish becomes important. Although chemical models are difficult to 
compare with human pathological conditions, chemically induced zebrafish models of ADHD have 
gained attention in developmental neuroscience research, including methylphenidate to chemically 
induce attention deficits and hyperactivity (Levin et al., 2011). Used to treat ADHD in humans, this 
drug presents developmental risk to the unborn fetus during gestation (Gray et al., 2007; Soileau, 
2008; Zhu et al., 2010). Interestingly, the zebrafish embryo exposed to methylphenidate 0-5 days 
past fertilization display  long-term behavioral deficits as adults (reduced choice accuracy and 
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diving response in three-chamber spatial learning task) but unaltered monoamine levels 30 days past 
fertilization  (Levin et al., 2011).   
 
6. Future directions 
Although pharmacological (Gonzalez et al., 2016; Levin et al., 2011; Spulber et al., 2014; 
Zhang et al., 2011) and genetic manipulations (Huang et al., 2015; Lange et al., 2018; Lange et al., 
2012; Martinez et al., 2016; Yang et al., 2018) provide consistent ADHD-like responses in 
zebrafish, many questions remain open (Table 2). For example, while larvae can present ADHD-
like phenotypes (Lange et al., 2018; Lange et al., 2012; Levin et al., 2011), it is unclear whether and 
how these behavioral changes persist in adults. Because ADHD is a neurodevelopmental disorder, 
studying behavioral and neurochemical changes across the lifespan is critical. Furthermore, ADHD 
is a complex, multifaceted and heterogeneous disorder that involves multiple neurotransmitter 
pathways beyond monoamines (Sergeant et al., 2003), and further studies using mutants directly 
targeting these pathways may improve the face, construct and predictive validity of zebrafish 
ADHD models. Finally, ADHD endophenotypes are not manifested by the disruption of one 
neuronal pathway, but from an interaction of shared circuits, making the discovery of new 
alternative treatments challenging (Mueller et al., 2017). A recent large-scale screen analyzed the 
behavioral effects of >10,000 drugs in larval zebrafish (Jordi et al., 2018) may foster pre-clinical 
development of new ADHD treatments and improve our understanding of how ADHD-related genes 
modulate a wide range of neural circuits.  
ADHD is frequently comorbid with other brain disorders, including (in the order of co-
occurrence) depression, substance abuse, obsessive–compulsive, conduct, borderline personality 
and anxiety-related disorders (Cumyn et al., 2009). Such high comorbidity may reflect not only co-
existing, independent pathologies, but can be part of shared, common transdiagnostic pathogenetic 
pathways between these conditions (Katzman et al., 2017). Cutting across different disorders, such 
comorbidities may reflect a true nature of ADHD pathobiology, thereby meriting further scrutiny in 
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both clinical studies and animal modeling. The overall ADHD genetic architecture remains poorly 
understood due to its complex multifactorial etiology and likely heterogeneity (Doyle, 2015). 
Consistent with recent research domain criteria (RDoCs) approach, this calls for novel zebrafish 
models of ADHD that would mimic its clinical comorbidities beyond ADHD-related domains. The 
RDoCs strategy defines psychopathologies as phenomena of multilevel neurobiological nature and 
assumes that underlying biological mechanisms are similar across species and individuals (Cuthbert, 
2014). There are 5 behavioral domains outlined in the RDoCs approach: general regulation and 
arousal behavior, positive valence, negative valence, and social interactions  (Anderzhanova et al., 
2017). Thus, due zebrafish brain and behavioral similarities (Gerlai, 2011; Higashijima et al., 2004; 
Kalueff et al., 2014b; Stewart et al., 2014), the analysis of the RDoC system appear as a novel 
approach for ADHD model validation allowing the discovery of the true nature of this disorder. 
Human ADHD shows overt sex differences in terms of incidence rates, clinical features and 
neurobiological mechanisms. In general, women present less severe  hyperactivity, inattention, 
impulsivity and externalizing problems (e.g. aggression and antisocial personality disorder) than 
male ADHD patients, but display higher intellectual impairments and more internalizing problems 
(e.g., anxiety, depression and eating disorders) (Arnett et al., 2015; Gershon, 2002). Various animal 
models also present sex differences in ADHD, including both behavioral and neurobiological 
responses (Gray, 1971; Jonasson, 2005; Volgin et al., 2018). In zebrafish, sex differences affect 
different behavioral domains, including the activity levels, an important factor when studying 
ADHD (Tran and Gerlai, 2013; Volgin et al., 2018).  For example, female zebrafish from the high 
activity sub-group prefer the top portion of tank compared with the low-activity females, whereas 
males do not show this preference (Tran and Gerlai, 2013). Although female and male zebrafish 
exhibit different activity profile, the sex differences in attention deficits tasks (e.g., 5CSRTT) has 
not yet been examined. 
Individual differences or “personality” traits also contribute to ADHD clinically, and are 
present in various animal models, including zebrafish (Dall et al., 2004; Tran and Gerlai, 2013; 
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Volgin et al., 2018). In humans, for example, low conscientiousness and  agreeableness are 
associated to inattention and hyperactivity, respectively (Nigg et al., 2002). Conduct problems in  
ADHD children (Sonuga-Barke et al., 2002) also represent an important personality trait correlating 
with ADHD severity. In zebrafish, individual differences are observed in several behavioral 
domains including locomotion, anxiety (Tran and Gerlai, 2013) and cognition (Toms and 
Echevarria, 2014). For example, high-, medium- and low- anxiety (Stewart et al., 2014) and activity 
levels (Tran and Gerlai, 2013) are typically observed in zebrafish novel tank task. As observed for 
sex differences, the individual attention-related phenotypes have not been examined in depth, but 
may represent an important factor in zebrafish ADHD models to consider. 
 In conclusion, zebrafish is rapidly becoming a critical novel model organism for ADHD 
research. Multiple zebrafish behavioral tests discussed here demonstrate similar behavioral aspects 
of this disorder, unraveling its genetic and neurochemical mechanisms.  Together, larval and adult 
models show consistent results through repeated manifestation of ADHD-related behaviors, 
providing important insights into the etiology of this disorder and offering a unique opportunity to 
study ADHD across the lifespan. Finally, combining behavior-based phenotyping with automated 
drug screening technologies, zebrafish emerge as a powerful animal model to discover novel drugs 
to treat ADHD.  
 
 
 
Acknowledgements 
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível 
Superior - Brazil (CAPES) - Finance Code 001 and Conselho Nacional de Desenvolvimento 
Científico e Tecnológico (CNPq). MOP receives funding from the British Academy (BA) and from 
the Liver Research Foundation (UK). DBR receives the CNPq research productivity grant 
(process number 307595/2015-3). His works is also supported by PROEX/CAPES fellowship grant 
AC
CE
PT
ED
 M
AN
US
CR
IPT
15 
 
 
 
(process number 23038.005848/2018-31; grant number 0737/2018). AVK is supported by the 
Russian Foundation for Basic Research (RFBR) grant 16-04-00851. The funders had no role in 
study design, decision to publish, or preparation of the manuscript. AVK is the Chair of the 
International Zebrafish Neuroscience Research Consortium (ZNRC), and this study was part of the 
ongoing, multi-lab ZNRC collaborative initiatives. 
 
References 
Adesman, A.R., 1992. Cognitive-Behavioral Therapy with Adhd Children - Child, Family, and School 
Interventions - Braswell,L, Bloomquist,Ml. J Dev Behav Pediatr 13, 313-314. 
Aizawa, H., 2013. Habenula and the asymmetric development of the vertebrate brain. Anat Sci Int 88, 1-9. 
Amsterdam, A., Hopkins, N., 2006. Mutagenesis strategies in zebrafish for identifying genes involved in 
development and disease. Trends Genet 22, 473-478. 
Anastopoulos, A.D., DuPaul, G.J., Weyandt, L.L., Morrissey-Kane, E., Sommer, J.L., Rhoads, L.H., 
Murphy, K.R., Gormley, M.J., Gudmundsdottir, B.G., 2018. Rates and Patterns of Comorbidity Among 
First-Year College Students With ADHD. J Clin Child Adolesc Psychol 47, 236-247. 
Anderzhanova, E., Kirmeier, T., Wotjak, C.T., 2017. Animal models in psychiatric research: The RDoC 
system as a new framework for endophenotype-oriented translational neuroscience. Neurobiol Stress 7, 
47-56. 
Arnett, A.B., Pennington, B.F., Willcutt, E.G., DeFries, J.C., Olson, R.K., 2015. Sex differences in ADHD 
symptom severity. J Child Psychol Psychiatry 56, 632-639. 
Beuchle, D., Schwarz, H., Langegger, M., Koch, I., Aberle, H., 2007. Drosophila MICAL regulates 
myofilament organization and synaptic structure. Mech Dev 124, 390-406. 
Bidwell, L.C., Balestrieri, S.G., Colby, S.M., Knopik, V.S., Tidey, J.W., 2018. Abstinence-induced 
withdrawal severity among adolescent smokers with and without ADHD: disentangling effects of nicotine 
and smoking reinstatement. Psychopharmacology (Berl) 235, 169-178. 
Bill, B.R., Balciunas, D., McCarra, J.A., Young, E.D., Xiong, T., Spahn, A.M., Garcia-Lecea, M., Korzh, 
V., Ekker, S.C., Schimmenti, L.A., 2008. Development and Notch signaling requirements of the zebrafish 
choroid plexus. PLoS One 3, e3114. 
Blaser, R.E., Rosemberg, D.B., 2012. Measures of anxiety in zebrafish (Danio rerio): dissociation of 
black/white preference and novel tank test. PloS one 7, e36931. 
Bonvicini, C., Faraone, S.V., Scassellati, C., 2016. Attention-deficit hyperactivity disorder in adults: A 
systematic review and meta-analysis of genetic, pharmacogenetic and biochemical studies. Mol 
Psychiatry 21, 872-884. 
Bouwknecht, J.A., Hijzen, T.H., van der Gugten, J., Maes, R.A., Hen, R., Olivier, B., 2001. Absence of 5-
HT(1B) receptors is associated with impaired impulse control in male 5-HT(1B) knockout mice. Biol 
Psychiatry 49, 557-568. 
Brunner, D., Buhot, M.C., Hen, R., Hofer, M., 1999. Anxiety, motor activation, and maternal-infant 
interactions in 5HT1B knockout mice. Behav Neurosci 113, 587-601. 
Buske, C., Gerlai, R., 2011. Shoaling develops with age in Zebrafish (Danio rerio). Progress in neuro-
psychopharmacology & biological psychiatry 35, 1409-1415. 
Cahill, G.M., 2007. Automated video image analysis of larval zebrafish locomotor rhythms. Methods in 
molecular biology 362, 83-94. 
Callaway, C.W., Rempel, N., Peng, R.Y., Geyer, M.A., 1992. Serotonin 5-HT1-like receptors mediate 
hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7, 
113-127. 
Carey, C.E., Agrawal, A., Bucholz, K.K., Hartz, S.M., Lynskey, M.T., Nelson, E.C., Bierut, L.J., Bogdan, 
R., 2016. Associations between Polygenic Risk for Psychiatric Disorders and Substance Involvement. 
Frontiers in genetics 7, 149. 
AC
CE
PT
ED
 M
NU
SC
RI
PT
16 
 
 
 
Carreno Gutierrez, H., Vacca, I., Pons, A.I., Norton, W.H.J., 2018. Automatic quantification of juvenile 
zebrafish aggression. J Neurosci Methods 296, 23-31. 
Champagne, D.L., Hoefnagels, C.C., de Kloet, R.E., Richardson, M.K., 2010. Translating rodent behavioral 
repertoire to zebrafish (Danio rerio): relevance for stress research. Behav Brain Res 214, 332-342. 
Cheon, K.A., Ryu, Y.H., Kim, Y.K., Namkoong, K., Kim, C.H., Lee, J.D., 2003. Dopamine transporter 
density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity 
disorder. Eur J Nucl Med Mol Imaging 30, 306-311. 
Chu, R.K., Rosic, T., Samaan, Z., 2017. Adult ADHD: Questioning Diagnosis and Treatment in a Patient 
with Multiple Psychiatric Comorbidities. Case Rep Psychiatry 2017, 1364894. 
Clark, K.J., Voytas, D.F., Ekker, S.C., 2011. A TALE of two nucleases: gene targeting for the masses? 
Zebrafish 8, 147-149. 
Comings, D.E., Gade-Andavolu, R., Gonzalez, N., Wu, S., Muhleman, D., Blake, H., Dietz, G., Saucier, G., 
MacMurray, J.P., 2000. Comparison of the role of dopamine, serotonin, and noradrenaline genes in 
ADHD, ODD and conduct disorder: multivariate regression analysis of 20 genes. Clin Genet 57, 178-
196. 
Cortese, S., 2012. The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what 
every clinician should know. European journal of paediatric neurology : EJPN : official journal of the 
European Paediatric Neurology Society 16, 422-433. 
Cortese, S., Angriman, M., 2017. Treatment of sleep disorders in youth with ADHD: what is the evidence 
from randomised controlled trials and how should the field move forward? Expert Rev Neurother 17, 525-
527. 
Creton, R., 2009. Automated analysis of behavior in zebrafish larvae. Behavioural brain research 203, 127-
136. 
Cumyn, L., French, L., Hechtman, L., 2009. Comorbidity in adults with attention-deficit hyperactivity 
disorder. Can J Psychiatry 54, 673-683. 
Cuthbert, B.N., 2014. The RDoC framework: facilitating transition from ICD/DSM to dimensional 
approaches that integrate neuroscience and psychopathology. World Psychiatry 13, 28-35. 
Dall, S.R.X., Houston, A.I., McNamara, J.M., 2004. The behavioural ecology of personality: consistent 
individual differences from an adaptive perspective. Ecology Letters 7, 734–739. 
Davids, E., Zhang, K., Tarazi, F.I., Baldessarini, R.J., 2003. Animal models of attention-deficit hyperactivity 
disorder. Brain Res Brain Res Rev 42, 1-21. 
Dougherty, D.D., Bonab, A.A., Spencer, T.J., Rauch, S.L., Madras, B.K., Fischman, A.J., 1999. Dopamine 
transporter density in patients with attention deficit hyperactivity disorder. Lancet 354, 2132-2133. 
Doyle, A.E., 2015. Commentary: Insights from across diagnostic boundaries: ADHD in the RDoC era--a 
commentary on Scerif and Baker (2015). J Child Psychol Psychiatry 56, 274-277. 
DuPaul, G.J., Jitendra, A.K., Volpe, R.J., Tresco, K.E., Lutz, J.G., Vile Junod, R.E., Cleary, K.S., Flammer, 
L.M., Mannella, M.C., 2006. Consultation-based academic interventions for children with ADHD: effects 
on reading and mathematics achievement. J Abnorm Child Psychol 34, 635-648. 
Egan, R.J., Bergner, C.L., Hart, P.C., Cachat, J.M., Canavello, P.R., Elegante, M.F., Elkhayat, S.I., Bartels, 
B.K., Tien, A.K., Tien, D.H., Mohnot, S., Beeson, E., Glasgow, E., Amri, H., Zukowska, Z., Kalueff, 
A.V., 2009. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. 
Behavioural brain research 205, 38-44. 
Fan, X., Bruno, K.J., Hess, E.J., 2012. Rodent models of ADHD. Curr Top Behav Neurosci 9, 273-300. 
Faraone, S.V., 2018. The pharmacology of amphetamine and methylphenidate: Relevance to the 
neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. 
Neuroscience and biobehavioral reviews 87, 255-270. 
Faraone, S.V., Perlis, R.H., Doyle, A.E., Smoller, J.W., Goralnick, J.J., Holmgren, M.A., Sklar, P., 2005. 
Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57, 1313-1323. 
Faraone, S.V., Sergeant, J., Gillberg, C., Biederman, J., 2003. The worldwide prevalence of ADHD: is it an 
American condition? World psychiatry : official journal of the World Psychiatric Association 2, 104-113. 
Farb, D.H., Ratner, M.H., 2014. Targeting the modulation of neural circuitry for the treatment of anxiety 
disorders. Pharmacological reviews 66, 1002-1032. 
Fetcho, J.R., Liu, K.S., 1998. Zebrafish as a model system for studying neuronal circuits and behavior. Ann 
N Y Acad Sci 860, 333-345. 
Field, L.L., Shumansky, K., Ryan, J., Truong, D., Swiergala, E., Kaplan, B.J., 2013. Dense-map genome 
scan for dyslexia supports loci at 4q13, 16p12, 17q22; suggests novel locus at 7q36. Genes Brain Behav 
12, 56-69. 
AC
CE
PT
ED
 M
NU
SC
RI
PT
17 
 
 
 
Fontana, B.D., Mezzomo, N.J., Kalueff, A.V., Rosemberg, D.B., 2018. The developing utility of zebrafish 
models of neurological and neuropsychiatric disorders: A critical review. Exp Neurol 299, 157-171. 
Franke, B., Faraone, S.V., Asherson, P., Buitelaar, J., Bau, C.H., Ramos-Quiroga, J.A., Mick, E., Grevet, 
E.H., Johansson, S., Haavik, J., Lesch, K.P., Cormand, B., Reif, A., International Multicentre persistent, 
A.C., 2012. The genetics of attention deficit/hyperactivity disorder in adults, a review. Mol Psychiatry 
17, 960-987. 
Freitag, C.M., Rohde, L.A., Lempp, T., Romanos, M., 2010. Phenotypic and measurement influences on 
heritability estimates in childhood ADHD. European child & adolescent psychiatry 19, 311-323. 
Gainetdinov, R.R., Jones, S.R., Caron, M.G., 1999. Functional hyperdopaminergia in dopamine transporter 
knock-out mice. Biol Psychiatry 46, 303-311. 
Gerlai, R., 2010a. High-throughput behavioral screens: the first step towards finding genes involved in 
vertebrate brain function using zebrafish. Molecules 15, 2609-2622. 
Gerlai, R., 2010b. Zebrafish antipredatory responses: a future for translational research? Behav Brain Res 
207, 223-231. 
Gerlai, R., 2011. A small fish with a big future: zebrafish in behavioral neuroscience. Rev Neurosci 22, 3-4. 
Gerlai, R., Lahav, M., Guo, S., Rosenthal, A., 2000. Drinks like a fish: zebra fish (Danio rerio) as a behavior 
genetic model to study alcohol effects. Pharmacol Biochem Behav 67, 773-782. 
Gershon, J., 2002. A meta-analytic review of gender differences in ADHD. J Atten Disord 5, 143-154. 
Gillis, J.J., Gilger, J.W., Pennington, B.F., DeFries, J.C., 1992. Attention deficit disorder in reading-disabled 
twins: evidence for a genetic etiology. Journal of abnormal child psychology 20, 303-315. 
Giros, B., Jaber, M., Jones, S.R., Wightman, R.M., Caron, M.G., 1996. Hyperlocomotion and indifference 
to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612. 
Gold, M.S., Blum, K., Oscar-Berman, M., Braverman, E.R., 2014. Low dopamine function in attention 
deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? Postgrad Med 126, 
153-177. 
Gonzalez, S.T., Remick, D., Creton, R., Colwill, R.M., 2016. Effects of embryonic exposure to 
polychlorinated biphenyls (PCBs) on anxiety-related behaviors in larval zebrafish. Neurotoxicology 53, 
93-101. 
Goode, A.P., Coeytaux, R.R., Maslow, G.R., Davis, N., Hill, S., Namdari, B., LaPointe, N.M.A., Befus, D., 
Lallinger, K.R., Bowen, S.E., Kosinski, A., McBroom, A.J., Sanders, G.D., Kemper, A.R., 2018. 
Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review. 
Pediatrics 141. 
Goodman, R., 1989. Genetic factors in hyperactivity. Bmj 298, 1407-1408. 
Goos, L.M., Crosbie, J., Payne, S., Schachar, R., 2009. Validation and extension of the endophenotype model 
in ADHD patterns of inheritance in a family study of inhibitory control. The American journal of 
psychiatry 166, 711-717. 
Gray, J.A., 1971. Sex differences in emotional behaviour in mammals including man: endocrine bases. Acta 
Psychol (Amst) 35, 29-46. 
Gray, J.D., Punsoni, M., Tabori, N.E., Melton, J.T., Fanslow, V., Ward, M.J., Zupan, B., Menzer, D., Rice, 
J., Drake, C.T., Romeo, R.D., Brake, W.G., Torres-Reveron, A., Milner, T.A., 2007. Methylphenidate 
administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and 
stress. J Neurosci 27, 7196-7207. 
Grossman, L., Utterback, E., Stewart, A., Gaikwad, S., Chung, K.M., Suciu, C., Wong, K., Elegante, M., 
Elkhayat, S., Tan, J., Gilder, T., Wu, N., Dileo, J., Cachat, J., Kalueff, A.V., 2010. Characterization of 
behavioral and endocrine effects of LSD on zebrafish. Behav Brain Res 214, 277-284. 
Hall, R.C., Myers, W.C., 2016. Challenges and Limitations to Treating ADHD in Incarcerated Populations. 
The journal of the American Academy of Psychiatry and the Law 44, 164-170. 
Halperin, J.M., Matier, K., Bedi, G., Sharma, V., Newcorn, J.H., 1992. Specificity of inattention, impulsivity, 
and hyperactivity to the diagnosis of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc 
Psychiatry 31, 190-196. 
Hawi, Z., Cummins, T.D., Tong, J., Johnson, B., Lau, R., Samarrai, W., Bellgrove, M.A., 2015. The 
molecular genetic architecture of attention deficit hyperactivity disorder. Mol Psychiatry 20, 289-297. 
Heintze, J., Luft, C., Ketteler, R., 2013. A CRISPR CASe for high-throughput silencing. Frontiers in genetics 
4, 193. 
Higashijima, S., Mandel, G., Fetcho, J.R., 2004. Distribution of prospective glutamatergic, glycinergic, and 
GABAergic neurons in embryonic and larval zebrafish. J Comp Neurol 480, 1-18. 
Higashijima, S., Masino, M.A., Mandel, G., Fetcho, J.R., 2003. Imaging neuronal activity during zebrafish 
behavior with a genetically encoded calcium indicator. J Neurophysiol 90, 3986-3997. 
A
CE
PT
ED
 M
AN
US
CR
IPT
18 
 
 
 
Howe, K., Clark, M.D., Torroja, C.F., Torrance, J., Berthelot, C., Muffato, M., Collins, J.E., Humphray, S., 
McLaren, K., Matthews, L., McLaren, S., Sealy, I., Caccamo, M., Churcher, C., Scott, C., Barrett, J.C., 
Koch, R., Rauch, G.J., White, S., Chow, W., Kilian, B., Quintais, L.T., Guerra-Assuncao, J.A., Zhou, Y., 
Gu, Y., Yen, J., Vogel, J.H., Eyre, T., Redmond, S., Banerjee, R., Chi, J., Fu, B., Langley, E., Maguire, 
S.F., Laird, G.K., Lloyd, D., Kenyon, E., Donaldson, S., Sehra, H., Almeida-King, J., Loveland, J., 
Trevanion, S., Jones, M., Quail, M., Willey, D., Hunt, A., Burton, J., Sims, S., McLay, K., Plumb, B., 
Davis, J., Clee, C., Oliver, K., Clark, R., Riddle, C., Elliot, D., Threadgold, G., Harden, G., Ware, D., 
Begum, S., Mortimore, B., Kerry, G., Heath, P., Phillimore, B., Tracey, A., Corby, N., Dunn, M., Johnson, 
C., Wood, J., Clark, S., Pelan, S., Griffiths, G., Smith, M., Glithero, R., Howden, P., Barker, N., Lloyd, 
C., Stevens, C., Harley, J., Holt, K., Panagiotidis, G., Lovell, J., Beasley, H., Henderson, C., Gordon, D., 
Auger, K., Wright, D., Collins, J., Raisen, C., Dyer, L., Leung, K., Robertson, L., Ambridge, K., 
Leongamornlert, D., McGuire, S., Gilderthorp, R., Griffiths, C., Manthravadi, D., Nichol, S., Barker, G., 
Whitehead, S., Kay, M., Brown, J., Murnane, C., Gray, E., Humphries, M., Sycamore, N., Barker, D., 
Saunders, D., Wallis, J., Babbage, A., Hammond, S., Mashreghi-Mohammadi, M., Barr, L., Martin, S., 
Wray, P., Ellington, A., Matthews, N., Ellwood, M., Woodmansey, R., Clark, G., Cooper, J., Tromans, 
A., Grafham, D., Skuce, C., Pandian, R., Andrews, R., Harrison, E., Kimberley, A., Garnett, J., Fosker, 
N., Hall, R., Garner, P., Kelly, D., Bird, C., Palmer, S., Gehring, I., Berger, A., Dooley, C.M., Ersan-
Urun, Z., Eser, C., Geiger, H., Geisler, M., Karotki, L., Kirn, A., Konantz, J., Konantz, M., Oberlander, 
M., Rudolph-Geiger, S., Teucke, M., Lanz, C., Raddatz, G., Osoegawa, K., Zhu, B., Rapp, A., Widaa, S., 
Langford, C., Yang, F., Schuster, S.C., Carter, N.P., Harrow, J., Ning, Z., Herrero, J., Searle, S.M., 
Enright, A., Geisler, R., Plasterk, R.H., Lee, C., Westerfield, M., de Jong, P.J., Zon, L.I., Postlethwait, 
J.H., Nusslein-Volhard, C., Hubbard, T.J., Roest Crollius, H., Rogers, J., Stemple, D.L., 2013. The 
zebrafish reference genome sequence and its relationship to the human genome. Nature 496, 498-503. 
Hruscha, A., Krawitz, P., Rechenberg, A., Heinrich, V., Hecht, J., Haass, C., Schmid, B., 2013. Efficient 
CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 140, 4982-4987. 
Huang, J., Zhong, Z., Wang, M., Chen, X., Tan, Y., Zhang, S., He, W., He, X., Huang, G., Lu, H., Wu, P., 
Che, Y., Yan, Y.L., Postlethwait, J.H., Chen, W., Wang, H., 2015. Circadian modulation of dopamine 
levels and dopaminergic neuron development contributes to attention deficiency and hyperactive 
behavior. J Neurosci 35, 2572-2587. 
Ingebretson, J.J., Masino, M.A., 2013. Quantification of locomotor activity in larval zebrafish: considerations 
for the design of high-throughput behavioral studies. Front Neural Circuits 7, 109. 
Ito, H., Yamamoto, N., 2009. Non-laminar cerebral cortex in teleost fishes? Biol Lett 5, 117-121. 
Jensen, P.S., Arnold, L.E., Richters, J.E., Severe, J.B., Vereen, D., Vitiello, B., Schiller, E., Hinshaw, S.P., 
Elliott, G.R., Conners, C.K., Wells, K.C., March, J., Swanson, J., Wigal, T., Cantwell, D.P., Abikoff, 
H.B., Hechtman, L., Greenhill, L.L., Newcorn, J.H., Pelham, W.E., Hoza, B., Kraemer, H.C., Grp, M.C., 
1999. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity 
disorder. Arch Gen Psychiat 56, 1073-1086. 
Jonasson, Z., 2005. Meta-analysis of sex differences in rodent models of learning and memory: a review of 
behavioral and biological data. Neurosci Biobehav Rev 28, 811-825. 
Jones, L.J., Norton, W.H., 2015. Using zebrafish to uncover the genetic and neural basis of aggression, a 
frequent comorbid symptom of psychiatric disorders. Behavioural brain research 276, 171-180. 
Jordi, J., Guggiana-Nilo, D., Bolton, A.D., Prahba, S., Ballotti, K., Herrera, K., Rennekamp, A.J., Peterson, 
R.T., Lutz, T.A., Engert, F., 2018. High-throughput screening for selective appetite modulators: A 
multibehavioral and translational drug discovery strategy. Science Advances 4. 
Kalueff, A.V., Echevarria, D.J., Stewart, A.M., 2014a. Gaining translational momentum: more zebrafish 
models for neuroscience research. Prog Neuropsychopharmacol Biol Psychiatry 55, 1-6. 
Kalueff, A.V., Gebhardt, M., Stewart, A.M., Cachat, J.M., Brimmer, M., Chawla, J.S., Craddock, C., Kyzar, 
E.J., Roth, A., Landsman, S., Gaikwad, S., Robinson, K., Baatrup, E., Tierney, K., Shamchuk, A., Norton, 
W., Miller, N., Nicolson, T., Braubach, O., Gilman, C.P., Pittman, J., Rosemberg, D.B., Gerlai, R., 
Echevarria, D., Lamb, E., Neuhauss, S.C., Weng, W., Bally-Cuif, L., Schneider, H., Zebrafish 
Neuroscience Research, C., 2013. Towards a comprehensive catalog of zebrafish behavior 1.0 and 
beyond. Zebrafish 10, 70-86. 
Kalueff, A.V., Stewart, A.M., Gerlai, R., 2014b. Zebrafish as an emerging model for studying complex brain 
disorders. Trends Pharmacol Sci 35, 63-75. 
Katzman, M.A., Bilkey, T.S., Chokka, P.R., Fallu, A., Klassen, L.J., 2017. Adult ADHD and comorbid 
disorders: clinical implications of a dimensional approach. BMC Psychiatry 17, 302. 
Kessler, R.C., Adler, L., Barkley, R., Biederman, J., Conners, C.K., Demler, O., Faraone, S.V., Greenhill, 
L.L., Howes, M.J., Secnik, K., Spencer, T., Ustun, T.B., Walters, E.E., Zaslavsky, A.M., 2006. The 
AC
CE
PT
ED
 M
AN
US
C
IPT
19 
 
 
 
prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity 
Survey Replication. Am J Psychiatry 163, 716-723. 
Knutson, B., Gibbs, S.E., 2007. Linking nucleus accumbens dopamine and blood oxygenation. 
Psychopharmacology 191, 813-822. 
Kokel, D., Peterson, R.T., 2008. Chemobehavioural phenomics and behaviour-based psychiatric drug 
discovery in the zebrafish. Brief Funct Genomic Proteomic 7, 483-490. 
Kostrzewa, R.M., Kostrzewa, J.P., Kostrzewa, R.A., Nowak, P., Brus, R., 2008. Pharmacological models of 
ADHD. J Neural Transm (Vienna) 115, 287-298. 
Krause, K.H., Dresel, S.H., Krause, J., Kung, H.F., Tatsch, K., 2000. Increased striatal dopamine transporter 
in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by 
single photon emission computed tomography. Neurosci Lett 285, 107-110. 
Kyun Ko, S., Chen, X., Yoon, J., Shin, I., 2011. Zebrafish as a good vertebrate model for molecular imaging 
using fluorescent probes. Chemical Society Reviews 40, 2120-2130. 
Lange, M., Froc, C., Grunwald, H., Norton, W.H.J., Bally-Cuif, L., 2018. Pharmacological analysis of 
zebrafish lphn3.1 morphant larvae suggests that saturated dopaminergic signaling could underlie the 
ADHD-like locomotor hyperactivity. Prog Neuropsychopharmacol Biol Psychiatry 84, 181-189. 
Lange, M., Neuzeret, F., Fabreges, B., Froc, C., Bedu, S., Bally-Cuif, L., Norton, W.H., 2013. Inter-
individual and inter-strain variations in zebrafish locomotor ontogeny. PLoS One 8, e70172. 
Lange, M., Norton, W., Coolen, M., Chaminade, M., Merker, S., Proft, F., Schmitt, A., Vernier, P., Lesch, 
K.P., Bally-Cuif, L., 2012. The ADHD-susceptibility gene lphn3.1 modulates dopaminergic neuron 
formation and locomotor activity during zebrafish development. Mol Psychiatry 17, 946-954. 
Lesch, K.P., Timmesfeld, N., Renner, T.J., Halperin, R., Roser, C., Nguyen, T.T., Craig, D.W., Romanos, J., 
Heine, M., Meyer, J., Freitag, C., Warnke, A., Romanos, M., Schafer, H., Walitza, S., Reif, A., Stephan, 
D.A., Jacob, C., 2008. Molecular genetics of adult ADHD: converging evidence from genome-wide 
association and extended pedigree linkage studies. J Neural Transm (Vienna) 115, 1573-1585. 
Levin, E.D., Bencan, Z., Cerutti, D.T., 2007. Anxiolytic effects of nicotine in zebrafish. Physiology & 
behavior 90, 54-58. 
Levin, E.D., Sledge, D., Roach, S., Petro, A., Donerly, S., Linney, E., 2011. Persistent behavioral impairment 
caused by embryonic methylphenidate exposure in zebrafish. Neurotoxicol Teratol 33, 668-673. 
Lieschke, G.J., Currie, P.D., 2007. Animal models of human disease: zebrafish swim into view. Nat Rev 
Genet 8, 353-367. 
Lo, H.S., Wang, Z., Hu, Y., Yang, H.H., Gere, S., Buetow, K.H., Lee, M.P., 2003. Allelic variation in gene 
expression is common in the human genome. Genome Res 13, 1855-1862. 
Lu, J., Peatman, E., Tang, H., Lewis, J., Liu, Z., 2012. Profiling of gene duplication patterns of sequenced 
teleost genomes: evidence for rapid lineage-specific genome expansion mediated by recent tandem 
duplications. BMC Genomics 13, 246. 
Luman, M., Tripp, G., Scheres, A., 2010. Identifying the neurobiology of altered reinforcement sensitivity 
in ADHD: a review and research agenda. Neuroscience and biobehavioral reviews 34, 744-754. 
MacPhail, R.C., Brooks, J., Hunter, D.L., Padnos, B., Irons, T.D., Padilla, S., 2009. Locomotion in larval 
zebrafish: Influence of time of day, lighting and ethanol. Neurotoxicology 30, 52-58. 
Marraccini, M.E., Weyandt, L.L., Gudmundsdottir, B.G., Oster, D.R., McCallum, A., 2017. Attention-
Deficit Hyperactivity Disorder: Clinical Considerations for Women. J Midwifery Womens Health 62, 
684-695. 
Martin, J., O'Donovan, M.C., Thapar, A., Langley, K., Williams, N., 2015. The relative contribution of 
common and rare genetic variants to ADHD. Transl Psychiatry 5, e506. 
Martinez, A.F., Abe, Y., Hong, S., Molyneux, K., Yarnell, D., Lohr, H., Driever, W., Acosta, M.T., Arcos-
Burgos, M., Muenke, M., 2016. An Ultraconserved Brain-Specific Enhancer Within ADGRL3 (LPHN3) 
Underpins Attention-Deficit/Hyperactivity Disorder Susceptibility. Biol Psychiatry 80, 943-954. 
Maximino, C., Lima, M.G., Batista Ede, J., Oliveira, K.R., Herculano, A.M., 2015. Interaction between 5-
HT1B receptors and nitric oxide in zebrafish responses to novelty. Neurosci Lett 588, 54-56. 
McCarthy, S., 2014. Pharmacological interventions for ADHD: how do adolescent and adult patient beliefs 
and attitudes impact treatment adherence? Patient preference and adherence 8, 1317-1327. 
McLean, D.L., Fetcho, J.R., 2004. Ontogeny and innervation patterns of dopaminergic, noradrenergic, and 
serotonergic neurons in larval zebrafish. J Comp Neurol 480, 38-56. 
Meng, X., Noyes, M.B., Zhu, L.J., Lawson, N.D., Wolfe, S.A., 2008. Targeted gene inactivation in zebrafish 
using engineered zinc-finger nucleases. Nature biotechnology 26, 695-701. 
Meshalkina, D.A., Song, C., Kalueff, A.V., 2017. Better lab animal models for translational neuroscience 
research and CNS drug development. Lab Anim (NY) 46, 91-92. 
AC
CE
PT
ED
MA
NU
SC
RI
PT
20 
 
 
 
Mezzomo, N.J., Fontana, B.D., Kalueff, A.V., Barcellos, L.J.G., Rosemberg, D.B., 2018. Understanding 
taurine CNS activity using alternative zebrafish models. Neurosci Biobehav Rev 90, 471-485. 
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F.R., Spencer, T., Grp, A.A.S., 
2001. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity 
disorder: A randomized, placebo-controlled, dose-response study. Pediatrics 108. 
Moens, C.B., Donn, T.M., Wolf-Saxon, E.R., Ma, T.P., 2008. Reverse genetics in zebrafish by TILLING. 
Brief Funct Genomic Proteomic 7, 454-459. 
Mongia, M., Hechtman, L., 2012. Cognitive behavior therapy for adults with attention-deficit/hyperactivity 
disorder: a review of recent randomized controlled trials. Curr Psychiatry Rep 14, 561-567. 
Mueller, A., Hong, D.S., Shepard, S., Moore, T., 2017. Linking ADHD to the Neural Circuitry of Attention. 
Trends Cogn Sci 21, 474-488. 
Nagel, G., Szellas, T., Huhn, W., Kateriya, S., Adeishvili, N., Berthold, P., Ollig, D., Hegemann, P., 
Bamberg, E., 2003. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc 
Natl Acad Sci U S A 100, 13940-13945. 
Nasiadka, A., Clark, M.D., 2012. Zebrafish breeding in the laboratory environment. ILAR J 53, 161-168. 
Nguyen, M., Yang, E., Neelkantan, N., Mikhaylova, A., Arnold, R., Poudel, M.K., Stewart, A.M., Kalueff, 
A.V., 2013. Developing 'integrative' zebrafish models of behavioral and metabolic disorders. Behav Brain 
Res 256, 172-187. 
Nigg, J.T., John, O.P., Blaskey, L.G., Huang-Pollock, C.L., Willcutt, E.G., Hinshaw, S.P., Pennington, B., 
2002. Big five dimensions and ADHD symptoms: links between personality traits and clinical symptoms. 
J Pers Soc Psychol 83, 451-469. 
Norton, W., Bally-Cuif, L., 2010. Adult zebrafish as a model organism for behavioural genetics. BMC 
Neurosci 11, 90. 
Norton, W.H., 2013. Toward developmental models of psychiatric disorders in zebrafish. Front Neural 
Circuits 7, 79. 
Orger, M.B., de Polavieja, G.G., 2017. Zebrafish Behavior: Opportunities and Challenges. Annu Rev 
Neurosci. 
Paclt, I., Koudelova, J., Krepelova, A., Uhlikova, P., Gazdikova, M., Bauer, P., 2005. Biochemical markers 
and genetic research of ADHD. Neuro Endocrinol Lett 26, 423-430. 
Panula, P., Chen, Y.C., Priyadarshini, M., Kudo, H., Semenova, S., Sundvik, M., Sallinen, V., 2010. The 
comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human 
neuropsychiatric diseases. Neurobiol Dis 40, 46-57. 
Parker, M.O., Brock, A.J., Sudwarts, A., Brennan, C.H., 2014. Atomoxetine reduces anticipatory responding 
in a 5-choice serial reaction time task for adult zebrafish. Psychopharmacology (Berl) 231, 2671-2679. 
Parker, M.O., Brock, A.J., Sudwarts, A., Teh, M.T., Combe, F.J., Brennan, C.H., 2015. Developmental role 
of acetylcholinesterase in impulse control in zebrafish. Front Behav Neurosci 9, 271. 
Parker, M.O., Ife, D., Ma, J., Pancholi, M., Smeraldi, F., Straw, C., Brennan, C.H., 2013. Development and 
automation of a test of impulse control in zebrafish. Front Syst Neurosci 7, 65. 
Parker, M.O., Millington, M.E., Combe, F.J., Brennan, C.H., 2012. Development and implementation of a 
three-choice serial reaction time task for zebrafish (Danio rerio). Behav Brain Res 227, 73-80. 
Parng, C., Seng, W.L., Semino, C., McGrath, P., 2002. Zebrafish: a preclinical model for drug screening. 
Assay Drug Dev Technol 1, 41-48. 
Plichta, M.M., Vasic, N., Wolf, R.C., Lesch, K.P., Brummer, D., Jacob, C., Fallgatter, A.J., Gron, G., 2009. 
Neural hyporesponsiveness and hyperresponsiveness during immediate and delayed reward processing in 
adult attention-deficit/hyperactivity disorder. Biological psychiatry 65, 7-14. 
Poelmans, G., Pauls, D.L., Buitelaar, J.K., Franke, B., 2011. Integrated genome-wide association study 
findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder. Am 
J Psychiatry 168, 365-377. 
Polanczyk, G.V., Salum, G.A., Sugaya, L.S., Caye, A., Rohde, L.A., 2015. Annual research review: A meta-
analysis of the worldwide prevalence of mental disorders in children and adolescents. Journal of child 
psychology and psychiatry, and allied disciplines 56, 345-365. 
Postlethwait, J.H., Woods, I.G., Ngo-Hazelett, P., Yan, Y.L., Kelly, P.D., Chu, F., Huang, H., Hill-Force, A., 
Talbot, W.S., 2000. Zebrafish comparative genomics and the origins of vertebrate chromosomes. Genome 
research 10, 1890-1902. 
Potter, A.S., Schaubhut, G., Shipman, M., 2014. Targeting the nicotinic cholinergic system to treat attention-
deficit/hyperactivity disorder: rationale and progress to date. CNS drugs 28, 1103-1113. 
Purper-Ouakil, D., Ramoz, N., Lepagnol-Bestel, A.M., Gorwood, P., Simonneau, M., 2011. Neurobiology 
of attention deficit/hyperactivity disorder. Pediatr Res 69, 69R-76R. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
21 
 
 
 
Rempel, N.L., Callaway, C.W., Geyer, M.A., 1993. Serotonin1B receptor activation mimics behavioral 
effects of presynaptic serotonin release. Neuropsychopharmacology 8, 201-211. 
Riccio, C.A., Homack, S., Jarratt, K.P., Wolfe, M.E., 2006. Differences in academic and executive function 
domains among children with ADHD Predominantly Inattentive and Combined Types. Arch Clin 
Neuropsychol 21, 657-667. 
Rihel, J., Prober, D.A., Arvanites, A., Lam, K., Zimmerman, S., Jang, S., Haggarty, S.J., Kokel, D., Rubin, 
L.L., Peterson, R.T., Schier, A.F., 2010. Zebrafish behavioral profiling links drugs to biological targets 
and rest/wake regulation. Science 327, 348-351. 
Rihel, J., Schier, A.F., 2012. Behavioral screening for neuroactive drugs in zebrafish. Dev Neurobiol 72, 
373-385. 
Rubia, K., Smith, A.B., Halari, R., Matsukura, F., Mohammad, M., Taylor, E., Brammer, M.J., 2009. 
Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during 
reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. The 
American journal of psychiatry 166, 83-94. 
Russell, V.A., 2007. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci 
Methods 161, 185-198. 
Russell, V.A., 2011. Overview of animal models of attention deficit hyperactivity disorder (ADHD). Curr 
Protoc Neurosci Chapter 9, Unit9 35. 
Russell, V.A., Sagvolden, T., Johansen, E.B., 2005. Animal models of attention-deficit hyperactivity 
disorder. Behav Brain Funct 1, 9. 
Safer, D.J., Zito, J.M., Fine, E.M., 1996. Increased methylphenidate usage for attention deficit disorder in 
the 1990s. Pediatrics 98, 1084-1088. 
Safren, S.A., Otto, M.W., Sprich, S., Winett, C.L., Wilens, T.E., Biederman, J., 2005. Cognitive-behavioral 
therapy for ADHD in medication-treated adults with continued symptoms. Behaviour research and 
therapy 43, 831-842. 
Sagvolden, T., Johansen, E.B., Aase, H., Russell, V.A., 2005a. A dynamic developmental theory of attention-
deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. 
Behav Brain Sci 28, 397-419; discussion 419-368. 
Sagvolden, T., Russell, V.A., Aase, H., Johansen, E.B., Farshbaf, M., 2005b. Rodent models of attention-
deficit/hyperactivity disorder. Biol Psychiatry 57, 1239-1247. 
Scheres, A., Dijkstra, M., Ainslie, E., Balkan, J., Reynolds, B., Sonuga-Barke, E., Castellanos, F.X., 2006. 
Temporal and probabilistic discounting of rewards in children and adolescents: effects of age and ADHD 
symptoms. Neuropsychologia 44, 2092-2103. 
Schmitz, S., Fulker, D.W., Mrazek, D.A., 1995. Problem behavior in early and middle childhood: An initial 
behavior genetic analysis. J Child Psychol Psyc 36, 1443-1458. 
Sergeant, J.A., Geurts, H., Huijbregts, S., Scheres, A., Oosterlaan, J., 2003. The top and the bottom of ADHD: 
a neuropsychological perspective. Neurosci Biobehav Rev 27, 583-592. 
Sharp, S.I., McQuillin, A., Marks, M., Hunt, S.P., Stanford, S.C., Lydall, G.J., Morgan, M.Y., Asherson, P., 
Curtis, D., Gurling, H.M., 2014. Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar 
disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome. American journal 
of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International 
Society of Psychiatric Genetics 165B, 373-380. 
Smoller, J.W., Biederman, J., Arbeitman, L., Doyle, A.E., Fagerness, J., Perlis, R.H., Sklar, P., Faraone, S.V., 
2006. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. 
Biol Psychiatry 59, 460-467. 
Soileau, E.J., Jr., 2008. Medications for adolescents with attention-deficit/hyperactivity disorder. Adolesc 
Med State Art Rev 19, 254-267, viii-ix. 
Sontag, T.A., Tucha, O., Walitza, S., Lange, K.W., 2010. Animal models of attention deficit/hyperactivity 
disorder (ADHD): a critical review. Atten Defic Hyperact Disord 2, 1-20. 
Sonuga-Barke, E.J., Dalen, L., Daley, D., Remington, B., 2002. Are planning, working memory, and 
inhibition associated with individual differences in preschool ADHD symptoms? Dev Neuropsychol 21, 
255-272. 
Spence, R., Gerlach, G., Lawrence, C., Smith, C., 2008. The behaviour and ecology of the zebrafish, Danio 
rerio. Biol Rev Camb Philos Soc 83, 13-34. 
Spencer, T.J., Biederman, J., Mick, E., 2007. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, 
comorbidities, and neurobiology. J Pediatr Psychol 32, 631-642. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
22 
 
 
 
Spulber, S., Kilian, P., Wan Ibrahim, W.N., Onishchenko, N., Ulhaq, M., Norrgren, L., Negri, S., Di Tuccio, 
M., Ceccatelli, S., 2014. PFOS induces behavioral alterations, including spontaneous hyperactivity that 
is corrected by dexamfetamine in zebrafish larvae. PLoS One 9, e94227. 
Stein, M.A., Blondis, T.A., Schnitzler, E.R., O'Brien, T., Fishkin, J., Blackwell, B., Szumowski, E., Roizen, 
N.J., 1996. Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98, 748-756. 
Sternat, T., Katzman, M.A., 2016. Neurobiology of hedonic tone: the relationship between treatment-
resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatric 
disease and treatment 12, 2149-2164. 
Stevenson, J., 1992. Evidence for a Genetic Etiology in Hyperactivity in Children. Behavior genetics 22, 
337-344. 
Stewart, A., Wu, N., Cachat, J., Hart, P., Gaikwad, S., Wong, K., Utterback, E., Gilder, T., Kyzar, E., 
Newman, A., Carlos, D., Chang, K., Hook, M., Rhymes, C., Caffery, M., Greenberg, M., Zadina, J., 
Kalueff, A.V., 2011. Pharmacological modulation of anxiety-like phenotypes in adult zebrafish 
behavioral models. Prog Neuropsychopharmacol Biol Psychiatry 35, 1421-1431. 
Stewart, A.M., Braubach, O., Spitsbergen, J., Gerlai, R., Kalueff, A.V., 2014. Zebrafish models for 
translational neuroscience research: from tank to bedside. Trends Neurosci 37, 264-278. 
Stewart, A.M., Ullmann, J.F., Norton, W.H., Parker, M.O., Brennan, C.H., Gerlai, R., Kalueff, A.V., 2015. 
Molecular psychiatry of zebrafish. Molecular psychiatry 20, 2-17. 
Terman, J.R., Mao, T., Pasterkamp, R.J., Yu, H.H., Kolodkin, A.L., 2002. MICALs, a family of conserved 
flavoprotein oxidoreductases, function in plexin-mediated axonal repulsion. Cell 109, 887-900. 
Thakkar, M.M., 2011. Histamine in the regulation of wakefulness. Sleep Med Rev 15, 65-74. 
Toms, C.N., Echevarria, D.J., 2014. Back to basics: searching for a comprehensive framework for exploring 
individual differences in zebrafish (Danio rerio) behavior. Zebrafish 11, 325-340. 
Tran, S., Gerlai, R., 2013. Individual differences in activity levels in zebrafish (Danio rerio). Behav Brain 
Res 257, 224-229. 
Tripp, G., Wickens, J., 2012. Reinforcement, dopamine and rodent models in drug development for ADHD. 
Neurotherapeutics 9, 622-634. 
Tropepe, V., Sive, H.L., 2003. Can zebrafish be used as a model to study the neurodevelopmental causes of 
autism? Genes Brain Behav 2, 268-281. 
Ulhaq, M., Orn, S., Carlsson, G., Morrison, D.A., Norrgren, L., 2013. Locomotor behavior in zebrafish 
(Danio rerio) larvae exposed to perfluoroalkyl acids. Aquat Toxicol 144-145, 332-340. 
van der Kooij, M.A., Glennon, J.C., 2007. Animal models concerning the role of dopamine in attention-
deficit hyperactivity disorder. Neurosci Biobehav Rev 31, 597-618. 
van Meel, C.S., Oosterlaan, J., Heslenfeld, D.J., Sergeant, J.A., 2005. Telling good from bad news: ADHD 
differentially affects processing of positive and negative feedback during guessing. Neuropsychologia 43, 
1946-1954. 
Volgin, A.D., Yakovlev, O.A., Demin, K.A., de Abreu, M.S., Alekseeva, P.A., Friend, A.J., Lakstygal, A.M., 
Amstislavskaya, T.G., Bao, W., Song, C., Kalueff, A.V., 2018. Zebrafish models for personalized 
psychiatry: Insights from individual, strain and sex differences, and modeling gene x environment 
interactions. J Neurosci Res. 
Wallis, D., Hill, D.S., Mendez, I.A., Abbott, L.C., Finnell, R.H., Wellman, P.J., Setlow, B., 2012. Initial 
characterization of mice null for Lphn3, a gene implicated in ADHD and addiction. Brain Res 1463, 85-
92. 
Wehmeier, P.M., Schacht, A., Barkley, R.A., 2010. Social and emotional impairment in children and 
adolescents with ADHD and the impact on quality of life. J Adolesc Health 46, 209-217. 
Weyandt, L.L., Oster, D.R., Marraccini, M.E., Gudmundsdottir, B.G., Munro, B.A., Zavras, B.M., Kuhar, 
B., 2014. Pharmacological interventions for adolescents and adults with ADHD: stimulant and 
nonstimulant medications and misuse of prescription stimulants. Psychology research and behavior 
management 7, 223-249. 
Wilens, T.E., Prince, J.B., Waxmonsky, J., Doyle, R., Spencer, T., Martelon, M., Evans, M., 2010. An Open 
Trial of Sustained Release Bupropion for Attention-Deficit/Hyperactivity Disorder in Adults with ADHD 
plus Substance Use Disorders. J ADHD Relat Disord 1, 25-35. 
Willner, P., 1986. Validation criteria for animal models of human mental disorders: learned helplessness as 
a paradigm case. Prog Neuropsychopharmacol Biol Psychiatry 10, 677-690. 
Winstanley, C.A., Eagle, D.M., Robbins, T.W., 2006. Behavioral models of impulsivity in relation to ADHD: 
translation between clinical and preclinical studies. Clin Psychol Rev 26, 379-395. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
23 
 
 
 
Wolraich, M.L., Hannah, J.N., Pinnock, T.Y., Baumgaertel, A., Brown, J., 1996. Comparison of diagnostic 
criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc 
Psychiatry 35, 319-324. 
Yang, L., Chang, S., Lu, Q., Zhang, Y., Wu, Z., Sun, X., Cao, Q., Qian, Y., Jia, T., Xu, B., Duan, Q., Li, Y., 
Zhang, K., Schumann, G., Liu, D., Wang, J., Wang, Y., Lu, L., 2018. A new locus regulating MICALL2 
expression was identified for association with executive inhibition in children with attention deficit 
hyperactivity disorder. Mol Psychiatry 23, 1014-1020. 
Zhang, F., Wang, L.P., Brauner, M., Liewald, J.F., Kay, K., Watzke, N., Wood, P.G., Bamberg, E., Nagel, 
G., Gottschalk, A., Deisseroth, K., 2007. Multimodal fast optical interrogation of neural circuitry. Nature 
446, 633-639. 
Zhang, J., Peterson, S.M., Weber, G.J., Zhu, X., Zheng, W., Freeman, J.L., 2011. Decreased axonal density 
and altered expression profiles of axonal guidance genes underlying lead (Pb) neurodevelopmental 
toxicity at early embryonic stages in the zebrafish. Neurotoxicol Teratol 33, 715-720. 
Zhang, L., Chang, S., Li, Z., Zhang, K., Du, Y., Ott, J., Wang, J., 2012. ADHDgene: a genetic database for 
attention deficit hyperactivity disorder. Nucleic Acids Res 40, D1003-1009. 
Zhu, N., Weedon, J., Dow-Edwards, D.L., 2010. The multifaceted effects of oral administration of 
methylphenidate in juvenile rats: anxiety, activity, and attention. Eur Neuropsychopharmacol 20, 236-
244. 
Zhuang, X., Gross, C., Santarelli, L., Compan, V., Trillat, A.C., Hen, R., 1999. Altered emotional states in 
knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 21, 52S-60S. 
 
 
 
 
 
 
 
 
 
 
Figure Captions 
Figure 1. Major ADHD-related proteins and their association with the monoaminergic 
systems (A. the dopaminergic system, B. the noradrenergic system, C. the serotoninergic system).  
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Figure 2. Schematic diagram outlining advantages of using zebrafish models to investigate 
ADHD. 
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Table 1. Overview of the neurotransmitter systems involved in ADHD and their genetic homology to zebrafish. 
Neuronal Pathways Genes Encoded proteins Biological Role Zebrafish orthologs genes Nucleotide identity rate (%) 
Zebrafish 
vs Human 
Zebrafish 
vs Mice 
Humans  
vs Mice 
Dopaminergic 
System 
SLC6A3 (C:5) Dopamine transporter Mediates the reuptakes of dopamine from the 
synapses. 
slc6a3 (C:16) 
 
89 
 
84 
 
87 
 DRD4 (C:11) Dopamine receptor 4 GPCR activated by the neurotransmitter 
dopamine. 
drd4a (C:25) & drd4b (C:7) 71 & 86 69 & 73 91 
 DRD2 (C:11) Dopamine receptor 2 GPCR activated by the neurotransmitter 
dopamine. 
drd2a (C:15) & drd2b (C: 5) 76 & 72 78 & 78 89 
 MAO-A (C:X) Monoamine oxidase A Key role in degradation of serotonin, noradrenalin 
and dopamine. 
mao (C:9) 83 83 80 
Noradrenergic 
System 
SLC6A2 (C:16) Noradrenaline Transporter Mediates the reuptakes of noradrenaline from the 
synapses. 
slc6a2 (C:7) 83 81 87 
 ADRA2A (C:10) Alpha-2A adrenergic 
receptor 
GPCR activated by the neurotransmitter 
noradrenalin. 
adra2a (C:22) 77 77 84 
 ADRA2C (C:4) Alpha-2C adrenergic 
receptor 
GPCR activated by the neurotransmitter 
noradrenalin. 
adra2c (C:1) 87 85 87 
 DBH (C:9) Dopamine beta-hydroxylase Synthetizes noradrenaline from dopamine. dbh (C:10) 70 69 81 
 PNMT (C:17) Phenylethanolamine N-
methyltransferase 
Converts noradrenaline to adrenaline. pnmt (C:12) 76 93 84 
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Serotoninergic 
System 
SLC6A4 (C:17) Serotonin transporter Mediate the reuptake of serotonin being Na+ and 
Cl dependent.  
slc6a4a (C:15) & slc6a4b (C:5) 
 
72 & 70 
 
73 & 72 
 
83 
 HTR1B (C:6) Hydroxytryptamine 
receptor 1B  
GPCR activated by the neurotransmitter serotonin.  
 
htr1b (C:17) 71 69 89 
 TPH2 (C:12) Tryptophan hydroxylase-2 Rate-limiting enzyme that synthetizes serotonin in 
brain. 
tph2 (C:18) 75 76 75 
Other ADHD-related 
mechanisms  
LPHN3 (C:4) Latrophilin 3 receptor GCPR that acts in signal transduction and cell 
adhesion. 
lphn3.1 (C:1) & lphn3.2 
(Unmapped) 
 
71 
 
76 
 
87 
 NOS1 (C:12) Nitric oxide synthase 1 Enzyme that synthetizes nitric oxide mediating 
several processes in brain. 
nos1 (C:5) 82 85 97 
 SNAP25 (C:20) Synaptosomal-associated 
protein 25 
Key role in axonal growth, synaptic plasticity and 
neurotransmitter release. 
snap25a (C:20) 79 82 83 
 ARRB2 (C:17) Beta-arrestin-2 protein Agonist-mediated desensitization of GCPR and 
role in cellular responses to different stimulus. 
arrb2a (C:10) 72 73 84 
 SYP (C:X) Synaptophysin protein Membrane protein of small synaptic vesicles in 
brain and endocrine cells. 
sypa (C:8) 67 69 78 
 HES1 (C:3) Transcription factor HES1 Transcriptional repressor of genes that require a 
helix-loop-helix protein for their transcription 
her6 (C:6) 77 76 88 
Average homology rate (%) 76.5 77.2 85.2 
Abbreviations: ADHD = Attention deficit hyperactivity disorder; C: = chromosome location; GCPR = G-coupled protein receptor; Na+ = Sodium anion; Cl = Chlorine. Note: NCBI database was used to 
assess the nucleotide sequence and to obtain the nucleotide identity rate (%) through blast analysis. 
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Table 2. Selected open questions in the field of zebrafish modeling ADHD 
 
Questions 
Conceptual 
 Can different ADHD types be model using zebrafish? 
 Is zebrafish a valid model for study ADHD phenotypes related to the monoamine 
systems?  
 How ADHD behavioral phenotypes change across lifespan (e.g., larvae versus adults)? 
 How does aging affect zebrafish ADHD-like responses? 
 Is the genetic homology of zebrafish high enough for ADHD translational research? 
 What are shared biochemical or/and molecular markers related to ADHD in humans, 
rodents and zebrafish? 
 Do sex differences play a key role in zebrafish models of ADHD? 
 Are there epigenetics processes that contribute to ADHD? 
 Can zebrafish models target clinical comorbidity of ADHD with other brain disorders? 
 Does zebrafish ‘personality’ affect the expression of ADHD-like phenotypes?  
Specific 
 Can stress affect the severity of (or mask) ADHD-like phenotypes in zebrafish models? 
 Are there individual differences in ADHD phenotypes in zebrafish populations? 
 Are there robust sex differences in ADHD severity (like those observed in humans)?  
 Can zebrafish and rodent genetic models of ADHD become basis of gene therapy?  
 Can new ADHD drugs be discovered by using larvae zebrafish for large-scale screening? 
 What are specific neural circuits involved in zebrafish ADHD models? 
 How can the environment affect zebrafish ADHD-like responses ant their severity across 
the lifespan? Are there gene x environment interactions for zebrafish ADHD models? 
 How RDoCs approaches could be used to model ADHD in zebrafish? 
 What are the mechanisms involved in the disruption of circadian cycle that leads to 
ADHD-like symptoms? 
 Are there any ADHD differences between zebrafish strains? 
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